A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

2018159 citationsJournal Articlehybrid Open Access

Authors

ClinicalTrials.gov, Identifier NCT00909025.

Good health and well-being

Published in: European Journal of Cancer

Volume 100, pp. 17-26

Field-Weighted Citation Impact: 2.83